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Background: The aim of this study was to determine the impact on the
outcome of serial B-type natriuretic peptide (BNP) changes during
follow-up in asymptomatic patients with  moderate aortic stenosis
(AS) and preserved left ventricular ejection fraction.
Methods: We prospectively screened 69 patients who underwent
comprehensive transthoracic echocardiography, BNP level measure-
ment at baseline and after every 6 or 12 months. Annualized BNP
changes were calculated as the difference between the last and
baseline BNP measurements divided by the duration of follow-up. The
primary endpoint was the occurrence of symptoms, aortic valve
replacement, or cardiovascular death.
Results: During a follow-up of 30  19 months, 43 patients experi-
enced a cardiac event. These patients were signiﬁcantly older (73  9Received for publication April 21, 2015. Accepted June 12, 2015.
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Introduction : Cette etude avait pour but de determiner l’effet des
variations du taux de peptide natriuretique de type B (BNP) mesure par
dosage repete durant le suivi des patients asymptomatiques
presentant une stenose aortique moderee ou grave et une fraction
d’ejection ventriculaire gauche preservee.
Methodes : Nous avons selectionne de manière prospective 69 pa-
tients ayant subi une echocardiographie transthoracique minutieuse
de même qu’un dosage initial du BNP, repete tous les 6 ou 12 mois
par la suite. La variation annualisee du taux de BNP a ete calculee
comme etant la difference entre le dernier dosage et le dosage initial,
laquelle etait ensuite divisee par la duree du suivi. Le paramètre
principal etait la survenue de symptômes, d’un remplacement valvu-
laire aortique ou du decès d’origine cardiovasculaire.Aortic stenosis (AS) is the most common valvular heart dis-
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recognition of symptoms can be difﬁcult and subjective,
ease. Current indications of aortic valve replacement are
mainly based on the presence of symptoms and/or left ven-
tricular (LV) dysfunction.2,3 Risk stratiﬁcation of asymp-
tomatic patients with AS and preserved LV ejection fraction
(LVEF) is challenging, and controversy persists regarding the
best timing for surgery. First of all, severity assessment is
performed by Doppler echocardiography, an operator-
dependent technique that requires expertise. Earlyespecially in the sedentary elderly population, leading to
concerns in regard to the “wait for symptoms” strategy.4,5
Some argue to avoid unnecessary operative-related mortality
by the “wait for symptoms” strategy; others claim that
asymptomatic patients could be operated early.6,7 Therefore,
the use of reproducible predictors of outcome, less dependent
on human factor error, is crucial to improve the management
of patients with AS and precisely determine which patients
could have the best beneﬁt from an “early surgery” strategy.
B-type natriuretic peptide (BNP) is a reproducible biomarker
predominantly secreted by ventricular cardiac myocytes in
response to increased wall stress preceding the occurrence of
symptoms.8 Previous studies already showed that single mea-
surement of a BNP level correlates with AS severity and their
harmful consequences on diastolic function, functional status,ll rights reserved.
vs 65  16 years; P ¼ 0.010), had more often dyslipidemia (79% vs
42%; P ¼ 0.038), more severe AS (peak velocity: 3.9  0.6 vs 3.5 
0.6 m/s; P ¼ 0.002), larger indexed left atrial area (10.2  2.5 vs 8.7
 1.9 cm2/m2; P ¼ 0.006), and a higher increase in annualized BNP
(þ90  155 vs þ7  49 pg/mL/y; P ¼ 0.010). Patients with higher
annualized BNP changes (> 20 pg/mL/y) had a signiﬁcantly lower
cardiac event-free survival (1 year: 63  8% vs 97  3%; 3 years: 31
 8% vs 68  8%; P < 0.001). Using the multivariate Cox proportional
hazards model, higher annualized BNP changes were signiﬁcantly
associated with increased risk of cardiac events (hazard ratio: 2.73,
95% conﬁdence interval: 1.27-5.86; P ¼ 0.010) after adjustment for
age, dyslipidemia, and echocardiographic parameters.
Conclusions: In asymptomatic patients with AS and preserved left
ventricular ejection fraction, the use of serial BNP changes may help to
anticipate development of class I indication for aortic valve
replacement.
Resultats : Durant un suivi de 30  19 mois, 43 patients ont eu un
evenement cardiaque. Ces patients etaient signiﬁcativement plus âges
(73  9 ans vs 65  16 ans; P ¼ 0,010), etaient plus nombreux à
presenter une dyslipidemie (79 % vs 42 %; P ¼ 0,038) ou une stenose
aortique grave (velocite maximale de 3,9  0,6 m/s vs 3,5  0,6 m/s;
P ¼ 0,002), avaient un volume auriculaire gauche indexe plus grand
(10,2  2,5 cm2/m2 vs 8,7  1,9 cm2/m2; P ¼ 0,006) et une
augmentation du taux annualise de BNP plus marquee (þ90  155
pg/ml/an vs þ7  49 pg/ml/an; P ¼ 0,010) par comparaison aux
autres sujets de l’etude. La survie sans evenement cardiaque etait en
outre signiﬁcativement inferieure (1 an : 63  8 % vs 97  3 %;
3 ans : 31  8 % vs 68  8 %; P < 0,001) chez les patients presentant
des variations annualisees du BNP plus elevees (> 20 pg/ml/an).
L’utilisation du modèle de risques proportionnels de Cox a revele une
association signiﬁcative entre les variations annualisees du BNP plus
elevees et un risque accru d’evenement cardiaque (rapport de risques
de 2,73; intervalle de conﬁance à 95 % : 1,27 à 5,86; P ¼ 0,010),
après l’ajustement tenant compte de l’âge, de la dyslipidemie et des
paramètres echocardiographiques.
Conclusions : Chez les patients asymptomatiques presentant une
stenose aortique et une fraction d’ejection ventriculaire gauche
preservee, le dosage repete du taux de BNP en vue d’en deceler les
variations pourrait permettre d’etablir une indication de classe I pour le
remplacement valvulaire aortique.
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Volume - 2015and symptomatic deterioration.9-11 Moreover, recent European
Society of Cardiology guidelines have suggested BNP level
measurement for risk stratiﬁcation in asymptomatic AS.2 Some
authors have evaluated serial BNP measurements in patients
with valvular heart disease demonstrating a better prediction of
outcome compared with single measurements.12,13 Accord-
ingly, we previously published a related paper providing inter-
esting insight into the relationship between the increase in serial
BNP and the presence of LV systolic and diastolic dysfunc-
tion.14 However, in AS, little is known about prediction of
outcome using serial changes in BNP levels. The aim of the
present study was to identify whether serial changes in BNP
levels during the follow-up of asymptomatic patients with AS
and preserved LVEF could predict outcome.Methods
Study population
Consecutive asymptomatic patients with at least moderate
AS (aortic valve area < 1.5 cm2) and preserved LVEF (>
50%) referred for clinical evaluation and Doppler echocardi-
ography to our heart valve clinic were prospectively screened.
A careful history and exercise testing conﬁrmed the asymp-
tomatic status. Patients with concomitant > mild mitral valve
disease or aortic regurgitation were excluded. Concomitantly,
BNP level measurement was performed at baseline and
repeated after at least 6 months of follow-up, and then, after
every 6 or 12 months, in all 69 included patients. The
institutional review boards approved the study and all patients
gave written informed consent.
Echocardiographic measurements
Transthoracic Doppler echocardiographic examination was
performed with a GE Vingmed VIVID 9 ultrasound system(Horton, Norway). The acquisitions were stored and subse-
quent off-line analyses were performed using a dedicated
workstation (EchoPac, General Electric Healthcare, Little
Chalfont, UK). The LV outﬂow tract area was multiplied by
the LV outﬂow tract velocity time integral measured by pulsed-
wave Doppler to calculate the LV stroke volume. The bi-apical
Simpson disk method was applied to measure the LV end-
diastolic and end-systolic volumes, and ejection fraction.
Pulsed-wave Doppler at mitral inﬂow was used to measure peak
E-wave and A-wave velocities and tissue Doppler imaging with
pulsed-wave Doppler at the level of septal and lateral mitral
annulus for e0 velocities. The E/e0 ratio was calculated using the
average of septal and lateral mitral annulus e0 peak velocity. The
LV global longitudinal myocardial deformation was evaluated
from standard 2D images with adequate frame rate ( 60/s) by
speckle tracking analysis. Manual tracing of the endocardial
borders on an end-systolic frame was performed, and auto-
matically tracking on subsequent frames was applied. Adequate
tracking for each segment was veriﬁed and manually corrected,
if necessary. The global longitudinal strain was the average of
the segment strains from apical 4-, 2-, and 3-chamber views.15
Peak and mean aortic gradient were calculated using the
simpliﬁed Bernoulli equation with the aortic transvalvular
maximal velocities obtained by continuous-wave Doppler, and
the continuity equation was used to calculate the aortic valve
area.16 The left atrial (LA) area was obtained by planimetry in
the apical 4-chamber view at end-systole. Systolic pulmonary
artery pressure was derived from the tricuspid regurgitant
maximal velocity using the modiﬁed Bernoulli equation and
the addition of estimated right atrial pressure.Serial BNP measurements
Venous blood samples were drawn at rest with chilled
ethylenediaminetetraacetic acid tubes, centrifuged immediately
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immunoﬂuorescence assay (Biosite, Beckman Coulter, San
Diego, CA). The assay detection was 1 pg/mL, and inter- and
intra-assay variations were 5% and 4%, respectively. Annual-
ized BNP changes were calculated as the BNP changes (dif-
ference between the last BNP measurement obtained during
the follow-up and the baseline BNP measurement at inclusion)
divided by the time between baseline measurement and last
follow-up measurement:
Annualized BNP changes ðpg=mL=yÞ
¼ ðLast BNP at follow-up Baseline BNP at inclusionÞ
Time of follow-up
Cardiac event-free survival
Patient follow-up was individualized and performed ac-
cording to current guidelines, that is, every 6 or 12 months.
Follow-up information was obtained after a complete medical
chart review and discussions with the patients and/or general
physicians. The follow-up was complete in 66 patients (96%).
The primary endpoint was the occurrence of the ﬁrst com-
posite endpoint deﬁned as the occurrence of symptoms, aortic
valve replacement (indicated by symptoms or LV dysfunction
according current class I indication),2,3 or cardiovascular
death.Statistical analysis
Data were expressed as mean  SD for continuous
variables and comparisons obtained with Student’s t-test.
Percentages were utilized for categorical variables and group
comparison obtained with the c2 test. Spearman’s correla-
tion coefﬁcient was applied to analyze the relationship
between annualized BNP changes and continuous param-
eters. To determine the independent predictors of annual-
ized BNP changes, variables with a P value < 0.20 in
univariate analysis were submitted to a stepwise backward
multiple-regression analysis. To avoid colinearity among AS
severity variables, we entered only peak aortic velocity in
the multivariate model. The impact of annualized BNP
changes on outcome was assessed according to median and
tertiles. Probabilities of cardiac event-free survival were
obtained by Kaplan-Meier estimates and compared with a
two-sided log-rank test. Cox proportional hazards models
were used both in univariable and multivariable analyses to
identify the independent predictors of cardiac event-free
survival. Gender and baseline BNP levels were forced
into the ﬁrst multivariable model regardless of the P value
as they may inﬂuence annualized BNP changes.9,17,18
Variables with a P value < 0.10 in univariable were
incorporated into the second multivariable model. To avoid
colinearity between parameters, statins, mean aortic pres-
sure gradient, and indexed valve area were not included in
the second model. Using the median of annualized BNP
changes as a cutoff value, sensitivity and speciﬁcity for the
prediction of the occurrence of events were determined
with a receiver operating characteristic (ROC) curve. A P
value  0.05 was considered statistically signiﬁcant. Sta-
tistical analyses were performed using IBM SPSS Advanced
Statistics 21.0.Results
Determinants of annualized BNP changes
Among the 69 included patients, mean BNP at baseline was
96  135 pg/mL (median: 62) and it signiﬁcantly increased
during the follow-up (last measurement: mean 180  233 pg/
mL [median 98]; P < 0.001). More than half of the patients
(61%, n ¼ 42) had more than 3 follow-up measurements, and
the duration of follow-up between the baseline and the last
measurement was 24  17 months. The mean of annualized
BNP changes was þ59  132 pg/mL/y (median: 20). Statis-
tically signiﬁcant correlations were found between annualized
BNP changes and age (r ¼ 0.271; P ¼ 0.024), aortic severity
parameters (peak aortic velocity: r ¼ 0.312; P ¼ 0.009),
indexed LA area (r ¼ 0.293; P ¼ 0.018), and baseline BNP
(r ¼ 0.275; P ¼ 0.022). There was a trend observed between
the E/e0 ratio (r ¼ 0.235; P ¼ 0.057) and annualized BNP
changes. There were no signiﬁcant correlations between
annualized BNP changes and LV mass (P ¼ 0.344), volume
(indexed end-diastolic: P ¼ 0.833), ejection fraction (P ¼
0.254), and global longitudinal strain (P ¼ 0.188). After
adjustment for age, baseline BNP, global longitudinal strain,
and E/e0 ratio, multivariable analysis identiﬁed the peak aortic
velocity (b ¼ 56.7  16.9; P ¼ 0.002) and the indexed LA
area (b ¼ 11.6  4.76; P ¼ 0.018) as independent de-
terminants of annualized BNP changes during follow-up.
Impact of annualized BNP changes on cardiac event-free
survival
During a global follow-up (baseline BNP measurement to the
last follow-up) of 30  19 months, 43 patients (62%) presented
a cardiac event. The duration of follow-up between the last BNP
measurement and the last follow-up was 6  11 months. Aortic
valve replacement was performed in 37 (54%) patients moti-
vated by the occurrence of symptoms in 27 (39%) patients and
by an abnormal exercise test showing symptoms clearly related to
AS in 10 (14%) patients. Among the 6 (9%) remaining events, 4
(6%) were related to the development of patient symptoms but
were treated medically because of prohibitive high surgical risk
and 2 (3%) patients died from a cardiovascular cause. Patients
with a cardiovascular event were signiﬁcantly older, and had
more often dyslipidemia, more severe AS, and a larger indexed
LA area (Tables 1 and 2). In addition, they had higher BNP at
follow-up and annualized BNP changes, but there was no dif-
ference according to BNP at baseline. Only those patients
experiencing a cardiovascular event had a signiﬁcant increase in
BNP level from baseline to follow-up (Fig. 1).
Cardiac event-free survival was 81%  5% and 49% 
6% at 1 and 3 years, respectively. According to the median of
annualized BNP changes, patients with lower annualized BNP
changes had a signiﬁcantly higher cardiac event-free survival (1
year: 97%  3% vs 63%  8%; 3 years: 68%  8% vs 31%
 8%; P < 0.001; Fig. 2). Similar results were found ac-
cording to tertiles of annualized BNP changes: patients in
tertile 3 had a signiﬁcantly reduced 2-year event-free survival
compared with tertile 1 (46  11% vs 82  8%; P ¼ 0.001;
Fig. 3). Using the multivariable Cox proportional hazard
model, higher annualized BNP changes were independently
associated with increased risk of cardiac events after adjust-
ment for sex and baseline BNP; and age, dyslipidemia, and
Table 1. Comparison of demographic and clinical data according to adverse cardiac events
Variables Whole cohort (n ¼ 69) No events (n ¼ 26, 38%) Events (n ¼ 43, 62%) P value
Demographic and clinical data
Age (y) 70  12 65  16 73  9 0.010
Male sex, n (%) 42 (61) 15 (58) 27 (63) 0.674
Body surface area (m2) 1.8  0.2 1.9  0.2 1.8  0.2 0.379
Heart rate (bpm) 70  11 70  10 71  12 0.735
Systolic arterial pressure (mm Hg) 146  19 145  20 147  19 0.673
Baseline BNP, pg/mL (median) 96  135 (62) 83  128 (49) 104  140 (67) 0.526
Risk factors
Hypertension, n (%) 37 (54) 13 (50) 24 (56) 0.639
Diabetes mellitus, n (%) 14 (20) 7 (27) 7 (16) 0.309
Dyslipidemia, n (%) 49 (71) 15 (42) 34 (79) 0.038
Coronary artery disease, n (%) 14 (20) 3 (12) 11 (26) 0.146
Smoking, n (%) 20 (29) 6 (23) 14 (33) 0.367
Atrial ﬁbrillation, n (%) 6 (9) 1 (4) 5 (12) 0.255
Medications
b-Blockers, n (%) 38 (55) 15 (58) 23 (53) 0.813
ACE inhibitors, n (%) 18 (26) 7 (27) 11 (26) 0.947
AR antagonists, n (%) 8 (12) 2 (8) 6 (14) 0.412
Diuretics, n (%) 14 (20) 5 (19) 9 (21) 0.828
Statins, n (%) 41 (62) 12 (46) 29 (67) 0.061
ACE, angiotensin converting enzyme; AR, angiotensin receptor.
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and indexed LA area (Table 3). The only other factor besides
annualized BNP changes identiﬁed as an independent pre-
dictor of cardiac events was the indexed LA area (hazard ratio
[HR]: 1.15, P ¼ 0.05). Similarly, tertile 3 of annualized BNP
changes was independently associated with a signiﬁcantly
worse cardiac event-free survival (HR: 2.20, P ¼ 0.036) as
compared with tertile 1. The ROC curve analysis (AUC ¼
0.79) showed good sensitivity and speciﬁcity of annualized
BNP changes > 20 pg/mL/y to predict the occurrence of
events in the next 6  11 months following the last BNP
measurement: 71% and 77%, respectively (Fig. 4).Discussion
The main ﬁndings of the present study, including
asymptomatic patients with preserved LVEF and moderate-
to-severe AS, are as follows: (1) patients with a cardiac
event had signiﬁcantly higher annualized BNP changes,
despite similar baseline BNP, than those without a cardiac
event during follow-up; and (2) patients with higherTable 2. Comparison of echocardiographic data according to adverse cardia
Variables Whole cohort (n ¼ 69)
AS severity
Peak aortic velocity (m/s) 3.8  0.7
Mean aortic pressure gradient (mm Hg) 37  14
Indexed valve area (cm2/m2) 0.53  0.13
LV geometry and function
Indexed mass (g/m2) 88  26
Indexed end-diastolic volume (mL/m2) 45  12
Indexed end-systolic volume (mL/m2) 15  5
Indexed stroke volume (mL/m2) 45  10
LV ejection fraction (%) 67  6
GLS (%) 20  3
E/e0 ratio 11  4
Indexed left atrial area (cm2/m2) 9.6  2.4
Systolic pulmonary arterial pressure (mm Hg) 36  9
AS, aortic stenosis; BNP, B-type natriuretic peptide; GLS, global longitudinal stannualized BNP changes (> 20 pg/mL/y) multiplied by 2.73
their risk of cardiac events, even after adjustment for age,
dyslipidemia, and echocardiographic parameters.
Pathophysiology of BNP release in AS
In AS, chronic pressure overload imposed on the LV leads
to progressive LV hypertrophy, a compensatory mechanism
aiming to maintain normal LV wall stress. However, at a
later stage, when this compensatory mechanism is over-
ridden, LV wall stress and ﬁlling pressure increase triggering
BNP activation and release.19 In symptomatic AS, BNP
release has been shown to reﬂect the elevation in LV ﬁlling
pressures.20 In symptomatic or asymptomatic severe AS with
structural impairment such as diastolic dysfunction, LA
dilatation, LV hypertrophy, and ﬁbrosis, elevated single BNP
level measurement is a marker of already elevated LV ﬁlling
pressures predicting poor short-term outcome.9,10 However,
in asymptomatic moderate-to-severe AS without signiﬁcant
structural changes, the baseline BNP level is potentially more
dependent on the overall patients’ picture (age, gender)
rather than on the degree and consequences of AS.18 Thisc events
No events (n ¼ 26, 38%) Events (n ¼ 43, 62%) P value
3.5  0.6 3.9  0.6 0.002
29  9 42  14 < 0.001
0.58  0.13 0.50  0.12 0.019
85  30 90  23 0.472
45  14 45  12 0.999
15  5 14  6 0.642
44  10 46  9 0.559
66  7 69  6 0.176
20  3 20  3 0.848
10  4 11  4 0.630
8.7  1.9 10.2  2.5 0.006
34  7 37  10 0.318
rain; LV, left ventricular.
Figure 3. Event-free survival according to tertiles of annualized BNP
changes.
Figure 1. Comparison of baseline BNP, follow-up BNP, and annualized
BNP changes (D) according to cardiac events.
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cohort and previous published data, even by our group.
Single BNP measurement provides a snapshot of the present
clinical situation but not of the evolution of the disease,
which is known to be highly individual. In contrast, the
progression of AS and its repercussions on LV are prone to
affect the BNP release over time with a gradual increase.
Higher annualized BNP changes can be the sign of the
progressive exhaustion of LV adaptation to the increased
afterload, which precedes the occurrence of symptoms. Of
note, in our cohort, indexed LA area, a sensitive marker of
elevated LV ﬁlling pressure,21 was an independent determi-
nant of annualized BNP changes.Figure 2. Event-free survival according to the median of annualized
BNP changes.Serial BNP changes and outcome in AS
In patients with AS, the prognostic value of single BNP
level measurement has been largely demonstrated. Different
cutoff values, ranging from 61 to 130 pg/mL, have been
related to the occurrence of symptoms, need for aortic valve
replacement, and cardiac-related death.9-11 To note, those
cutoff values were not adjusted to counteract the interindi-
vidual variation of BNP levels related to age and gender. To
address this issue, Clavel et al. have shown that BNP
normalized to age and sex was also highly predictive of out-
comes in a large cohort.22 However, there are few data
regarding serial BNP changes for predicting outcome in
asymptomatic patients with AS and preserved LVEF. In a
small cohort of 29 asymptomatic patients with moderate-to-
severe AS, the average rate of increase in the NT-proBNP
level was greater in patients who developed symptoms
compared with those who remained asymptomatic (þ26
vs þ7.2 pmol/L; P ¼ 0.014).17 Similarly, in a group of 43
initially asymptomatic patients, a mean BNP increase from
188 to 486 pg/mL was noticed in 14 patients developingTable 3. Cox proportional hazard regression analysis for the prediction
of adverse cardiac events according to median of annualized B-type
natriuretic peptide changes
Analysis
BNP > 20 pg/mL/y
HR 95% CI P
Univariable 3.48 1.81-6.69 < 0.001
Sex and baseline BNP-adjusted 3.48 1.81-6.69 < 0.001
Age- and dysl.-adjusted 3.49 1.77-6.86 < 0.001
Echo-adjusted 2.56 1.23-5.34 0.012
Age-, dysl., and echo-adjusted 2.73 1.27-5.86 0.010
Echocardiographic variables included in the model were peak aortic ve-
locity and indexed left atrial area.
BNP, B-type natriuretic peptide; CI, conﬁdence interval; dysl., dyslipi-
demia; HR, hazard ratio.
Figure 4. Receiver operating characteristic curve analysis for the
prediction of adverse cardiac events using annualized BNP changes.
Annualized BNP changes > 20 pg/mL/y (blue square) showed a
good sensitivity of 71%, speciﬁcity of 77%, and an area under the
curve of 0.79.
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one.9 Unfortunately, in both studies, time-dependent analysis
and cofactors associated with changes in the serial BNP level
were not assessed. Our results are the ﬁrst to demonstrate that
patients with higher annualized BNP changes (>20 pg/mL/y)
had a signiﬁcantly lower cardiac event-free survival multiplied
by 2.73 the risk of cardiac events, even after adjustment for
cofactors. Moreover, only those patients experiencing a cardiac
event had a signiﬁcant increase in BNP level from baseline to
follow-up, without any differences in BNP at baseline.
Clinical implications
Early recognition of symptoms in asymptomatic patients
with moderate-to-severe AS and preserved LVEF is essential
according to the associated worse individual prognosis justi-
fying the immediate referral for aortic valve replacement. As
the most common initial symptom is dyspnea (i.e., a
nonspeciﬁc and subjective symptom), serial BNP changes, an
independent predictor of cardiac events in our study, may
help to deﬁne the best timing of aortic valve replacement. To
note, the only other independent predictor of cardiac events
identiﬁed in our cohort was the indexed LA area, already
associated with a worse outcome in a previous study.15 Hence,
it might be useful to assess an individual baseline BNP level
and then monitor the serial BNP changes.23 An increase in
serial BNP levels can identify patients with a more rapid
disease process who could develop symptoms and may beneﬁt
form an “early surgery” strategy. Moreover, a parallel can be
established between echocardiographic assessment of AS
progression and serial BNP measurements. In fact, the pro-
gression of AS severity, using aortic jet velocity, has been
shown to be quite variable among patients, as serial BNPmeasurements in our cohort. The rate of progression of ste-
nosis was signiﬁcantly higher in patients who presented car-
diac events than those did not.24 However, AS severity
assessment using Doppler echocardiography requires experi-
enced sonographers who are aware of technical pitfalls,
compared with BNP level measurement being reproducible,
low cost, and not operator dependent. In our cohort, a cutoff
value of annualized BNP changes > 20 pg/mL/y provided a
sensitivity and speciﬁcity of 71% and 77%, respectively, to
predict the occurrence of events. We believe that serial BNP
measurements should be integrated into the AS management
algorithm as complement to clinical and echocardiographic
evaluation.23 However, further larger studies addressing
mortality reduction after aortic valve replacement guided by
serial BNP changes are needed to conﬁrm the beneﬁt of this
strategy.
Limitations
The duration of follow-up and the interval between BNP
measurements were not standardized in the entire cohort as
individual management was left to the discretion of the
cardiologist. The use of annualized BNP changes may partially
temper such limitation. Furthermore, all patients were fol-
lowed up in our heart valve clinic and received standard
clinical management. We cannot exclude that other factors,
such as medical therapy or changes in renal function, might
have inﬂuenced the BNP changes. The majority of the re-
ported cardiac events were aortic valve replacement indicated
by symptoms for which the evaluation remains subjective.
However, the occurrence of symptoms is a current class I
indication for surgery and reﬂects general practice.Conclusions
In our cohort of asymptomatic patients with AS and pre-
served LVEF, higher annualized BNP changes (> 20 pg/mL/
y) were associated with a signiﬁcantly lower cardiac event-free
survival multiplied by 2.73 the risk of cardiac events. More-
over, compared with patients remaining free from a cardiac
event, those experiencing a cardiac event had a progressive
increase in BNP level from baseline to follow-up despite the
absence of signiﬁcant differences in BNP at baseline. Conse-
quently, serial BNP changes may be useful to anticipate the
development of class I indication for aortic valve replacement
and to predict outcome.Acknowledgements
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